Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Zoetis Management

Management Kriterienprüfungen 3/4

Zoetis' CEO ist Kristin Peck, ernannt in Jan 2020, hat eine Amtszeit von 4.33 Jahren. Die jährliche Gesamtvergütung beträgt $15.24M, bestehend aus 7.9% Gehalt und 92.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.018% der Aktien des Unternehmens, im Wert von €12.57M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2 Jahre bzw. 10.5 Jahre.

Wichtige Informationen

Kristin Peck

Geschäftsführender

US$15.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	7.9%
Amtszeit als Geschäftsführer	4.4yrs
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	2.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	10.5yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kristin Peck im Vergleich zu den Einnahmen von Zoetis verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$15m	US$1m	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	US$14m	US$1m	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$13m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$2b
Dec 31 2020	US$10m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$3m	US$690k	US$2b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$1b
Dec 31 2018	US$3m	US$675k	US$1b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$978m
Dec 31 2017	US$3m	US$655k	US$864m

Vergütung im Vergleich zum Markt: KristinDie Gesamtvergütung ($USD15.24M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD5.35M).

Entschädigung vs. Einkommen: KristinDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Kristin Peck (53 yo)

4.4yrs

Amtszeit

US$15,237,853

Vergütung

Ms. Kristin C. Peck serves as an Independent Director at BlackRock, Inc. since joining on September 29, 2021. She has been the Chief Executive Officer of Zoetis Inc. since January 01, 2020 and its Director...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kristin Peck	CEO & Director	4.4yrs	US$15.24m	0.018% $ 12.7m
Wetteny Joseph	Executive VP & CFO	3yrs	US$4.25m	0.00019% $ 137.1k
Wafaa Mamilli	EVP, Chief Digital & Tech. Officer	1.6yrs	US$2.69m	0.0015% $ 1.1m
Heidi Chen	Employee Advisor	less than a year	US$2.60m	0.0069% $ 5.0m
Robert Polzer	Executive VP and President of Research & Development	9.4yrs	US$2.44m	0.00094% $ 678.3k
Steven Frank	Vice President of Investor Relations	no data	keine Daten	keine Daten
Roxanne Lagano	Executive VP	less than a year	keine Daten	0.0034% $ 2.5m
William Price	VP & Chief Communications Officer	no data	keine Daten	keine Daten
Jeannette Astorga	Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer	3.8yrs	keine Daten	0.00015% $ 108.2k
Nick Ashton	Executive VP and President of Global Manufacturing & Supply	2.1yrs	keine Daten	0.00014% $ 101.0k
Jamie Brannan	Executive VP and Group President International Operations of Aquaculture & Global Diagnostics	no data	keine Daten	0.00043% $ 310.3k
Rimma Driscoll	Executive VP and Head of Global Strategy	1.6yrs	keine Daten	0.0010% $ 757.7k

2.1yrs

Durchschnittliche Betriebszugehörigkeit

52.5yo

Durchschnittliches Alter

Erfahrenes Management: ZOEDas Führungsteam des Unternehmens gilt als erfahren (2 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kristin Peck	CEO & Director	4.7yrs	US$15.24m	0.018% $ 12.7m
Louise Parent	Independent Director	10.8yrs	US$370.00k	0.0030% $ 2.2m
Michael McCallister	Independent Non-Executive Chairman	11.4yrs	US$490.00k	0.0057% $ 4.1m
Paul Bisaro	Independent Director	9.1yrs	US$340.00k	0.0048% $ 3.4m
Frank D'Amelio	Independent Director	11.9yrs	US$340.50k	0.0032% $ 2.3m
Sanjay Khosla	Independent Director	11yrs	US$340.00k	0.0022% $ 1.6m
Robert Scully	Independent Director	11yrs	US$365.00k	0.0043% $ 3.1m
Gavin D. Hattersley	Independent Director	less than a year	keine Daten	0.00017% $ 122.7k
Gregory Norden	Independent Director	11.4yrs	US$365.00k	0.0033% $ 2.4m
Willie Reed	Independent Director	10.3yrs	US$370.00k	0.0022% $ 1.6m
Vanessa Broadhurst	Independent Director	1.9yrs	US$341.00k	0.00022% $ 158.8k
Antoinette Leatherberry	Independent Director	3.5yrs	US$340.00k	0.00049% $ 353.6k

10.5yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: ZOEDie Vorstandsmitglieder sind sehr erfahren ( 10.5 ).

Zoetis Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Zoetis Inc. Announces Retirement of Linda Rhodes as Board of Directors

Zoetis Inc. Announces Executive Changes

Zoetis Inc., Annual General Meeting, May 22, 2024

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Insufficient new directors

Zoetis Inc. Announces Appointment of Ester Banque as Executive Vice President and President, U.S. Operations

Recent updates

First quarter dividend of US$0.43 announced

Zoetis Inc. Announces Retirement of Linda Rhodes as Board of Directors

Zoetis Inc. Declares Dividend for the Third Quarter of 2024, Payable on September 4, 2024

Now 20% undervalued after recent price drop

Zoetis Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$1.31 (vs US$1.19 in 1Q 2023)

Phibro Animal Health Corporation (NasdaqGM:PAHC) entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. (NYSE:ZTS) for approximately $350 million.

Zoetis Inc. Announces Executive Changes

Zoetis Inc., Annual General Meeting, May 22, 2024

Upcoming dividend of US$0.43 per share

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Now 21% undervalued after recent price drop

Full year 2023 earnings released: EPS: US$5.08 (vs US$4.51 in FY 2022)

Dividend of US$0.43 announced

Zoetis Inc. Declares Second Quarter 2024 Dividend, Payable on June 4, 2024

Upcoming dividend of US$0.43 per share at 0.9% yield

Insufficient new directors

Zoetis Inc. Declares Dividend for the First Quarter of 2024, Payable on March 1, 2024

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$1.30 (vs US$1.13 in 3Q 2022)

Now 21% undervalued after recent price drop

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 1, 2023

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH.

Second quarter 2023 earnings released: EPS: US$1.45 (vs US$1.13 in 2Q 2022)

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Announces Appointment of Ester Banque as Executive Vice President and President, U.S. Operations

JAB Holdings B.V. acquired an unknown majority interest in Pumpkin Insurance Services Inc. from Zoetis Inc. (NYSE:ZTS).

Zoetis Inc. Declares Dividend for Third Quarter of 2023, Payable on September 1, 2023

Zoetis Inc. Announces U.S. Food and Drug Administration Approves Librela™ (Bedinvetmab Injection) for Control of Pain Associated with Osteoarthritis in Dogs

Zoetis Inc. Maintains Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: EPS: US$1.19 (vs US$1.26 in 1Q 2022)

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Provides Earning Guidance for Full Year 2023

Full year 2022 earnings released: EPS: US$4.51 (vs US$4.29 in FY 2021)

Zoetis Inc. Declares Second Quarter 2023 Dividend, Payable on June 1, 2023

Zoetis Inc. Announces Termination of Glenn David as Executive Vice President and Group President, U.S. Operations

Upcoming dividend of US$0.38 per share

Zoetis Inc. Declares Dividend for the First Quarter of 2023 Dividend, Payable on March 1, 2023

Third quarter 2022 earnings released: EPS: US$1.13 (vs US$1.17 in 3Q 2021)

Zoetis Inc. Provides Earnings Guidance for the Full Year 2022

Zoetis Inc. Announces Management Changes, Effective November 1, 2022

Upcoming dividend of US$0.33 per share

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2022, Payable on December 1, 2022

Second quarter 2022 earnings released: EPS: US$1.13 (vs US$1.08 in 2Q 2021)

Zoetis Inc. Provides Earnings Guidance for the Full Year 2022

Zoetis Inc. Appoints Vanessa Broadhurst to Its Board of Directors

Upcoming dividend of US$0.33 per share

Zoetis Inc.(NYSE:ZTS) dropped from Russell 1000 Value-Defensive Index

Zoetis Inc. (NYSE:ZTS) acquired Basepaws

Independent Director recently sold €286k worth of stock

Zoetis Inc. (NYSE:ZTS) entered into an agreement to acquire Basepaws.

Zoetis Inc. Declares Dividend for the Third Quarter of 2022, Payable on September 1, 2022

First quarter 2022 earnings released: EPS: US$1.26 (vs US$1.18 in 1Q 2021)

Zoetis Inc. Revises Earnings Guidance for the Year 2022

Zoetis Inc. Announces Retirement of Roman Trawicki as Executive Vice President and President, Effective July 31, 2022

Upcoming dividend of US$0.33 per share

Zoetis Inc., Annual General Meeting, May 19, 2022

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Zoetis Inc. Provides Earnings Guidance for the Full Year 2022

Zoetis Inc. Declares Dividend for the Second Quarter 2022, Payable on June 1, 2022

Zoetis Inc. Announces FDA Approval of Solensia™ (frunevetmab injection) to Control Osteoarthritis Pain in Cats

Upcoming dividend of US$0.33 per share

Investor sentiment deteriorated over the past week

Zoetis Inc. (NYSE:ZTS) announces an Equity Buyback for $3,500 million worth of its shares.

CEO & Director recently sold €497k worth of stock